Induced pluripotent stem (iPS) cells have great potential for personalized regenerative medicine. Although several different methods for generating iPS cells have been reported, improvement of safety and efficiency is imperative. In this study, we tested the feasibility of using a triple tyrosine mutant AAV2 (Y444+500+730F) vector, designated AAV2.3m, to generate iPS cells. We developed a polycistronic rAAV2.3m vector expressing three reprogramming factors, Klf4, Oct4, and Sox2, and then used this vector to infect mouse adipose-derived mesenchymal stem cells (AT-MSCs) to induce the generation of iPS cells. We demonstrated that (1) the triple tyrosine mutant AAV2 vector is able to reprogram mouse adult adipose tissue-derived stem cells into the pluripotent state. Those rAAV2.3m-derived iPS (rAAV2.3m-iPS) cells express endogenous pluripotency-associated genes including Oct4, Sox2, and SSEA-1, and form teratomas containing multiple tissues in vivo; (2) c-myc, an oncogene, is dispensable in rAAV2.3m-mediated cellular reprogramming; and (3) transgene expression is undetectable after reprogramming, whereas vector DNA is detectable, indicating that transgenes are silenced. These results indicated the rAAV vector may have some advantages in generating iPS cells.
Get full access to this article
View all access options for this article.
References
1.
AasenT., and BelmonteJ.C. (2010). Isolation and cultivation of human keratinocytes from skin or plucked hair for the generation of induced pluripotent stem cells. Nat. Protoc., 5, 371–382.
2.
AokiT., OhnishiH., OdaY., et al. (2010). Generation of induced pluripotent stem cells from human adipose-derived stem cells without c-MYC. Tissue Eng. Part A, 16, 2197–2206.
3.
BlinG., NuryD., StefanovicS., et al. (2010). A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. J. Clin. Invest., 120, 1125–1139.
4.
BrambrinkT., ForemanR., WelsteadG.G., et al. (2008). Sequential expression of pluripotency markers during direct reprogramming of mouse somatic cells. Cell Stem Cell, 2, 151–159.
5.
ChenT., YuanD., WeiB., et al. (2010). E-cadherin-mediated cell–cell contact is critical for induced pluripotent stem cell generation. Stem Cells, 28, 1315–1325.
6.
ChoH.J., LeeC.S., KwonY.W., et al. (2010). Induction of pluripotent stem cells from adult somatic cells by protein-based reprogramming without genetic manipulation. Blood, 116, 386–395.
7.
DayaS., and BernsK.I. (2008). Gene therapy using adeno-associated virus vectors. Clin. Microbiol. Rev., 21, 583–593.
8.
DuanD., SharmaP., YangJ., et al. (1998). Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J. Virol., 72, 8568–8577.
9.
EminliS., UtikalJ., ArnoldK., et al. (2008). Reprogramming of neural progenitor cells into induced pluripotent stem cells in the absence of exogenous Sox2 expression. Stem Cells, 26, 2467–2474.
10.
EstebanM.A., WangT., QinB., et al. (2010). Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. Cell Stem Cell, 6, 71–79.
11.
FlotteT.R., TrapnellB.C., HumphriesM., et al. (2011). Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: Interim results. Hum. Gene Ther., 22, 1239–1247.
12.
FusakiN., BanH., NishiyamaA., et al. (2009). Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci., 85, 348–362.
13.
GriegerJ.C., and SamulskiR.J. (2012). Adeno-associated virus vectorology, manufacturing, and clinical applications. Methods Enzymol., 507, 229–254.
14.
HottaA., and EllisJ. (2008). Retroviral vector silencing during iPS cell induction: An epigenetic beacon that signals distinct pluripotent states. J. Cell Biochem., 105, 940–948.
15.
JiaF., WilsonK.D., SunN., et al. (2010). A nonviral minicircle vector for deriving human iPS cells. Nat. Methods, 7, 197–199.
16.
KajiK., NorrbyK., PacaA., et al. (2009). Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature, 458, 771–775.
17.
KeelerA.M., ConlonT., WalterG., et al. (2012). Long-term correction of very long-chain acyl-CoA dehydrogenase deficiency in mice using AAV9 gene therapy. Mol. Ther., 20, 1131–1138.
18.
KimJ.B., ZaehresH., Arauzo-BravoM.J., and ScholerH.R. (2009). Generation of induced pluripotent stem cells from neural stem cells. Nat. Protoc., 4, 1464–1470.
19.
KunisatoA., WakatsukiM., KodamaY., et al. (2010). Generation of induced pluripotent stem cells by efficient reprogramming of adult bone marrow cells. Stem Cells Dev., 19, 229–238.
20.
LiM., JayandharanG.R., LiB., et al. (2010). High-efficiency transduction of fibroblasts and mesenchymal stem cells by tyrosine-mutant AAV2 vectors for their potential use in cellular therapy. Hum. Gene Ther., 21, 1527–1543.
21.
LiW., ZhouH., AbujarourR., et al. (2009). Generation of human-induced pluripotent stem cells in the absence of exogenous Sox2. Stem Cells, 27, 2992–3000.
22.
MaguireA.M., SimonelliF., PierceE.A., et al. (2008). Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med., 358, 2240–2248.
23.
MaliP., ChouB.K., YenJ., et al. (2010). Butyrate greatly enhances derivation of human induced pluripotent stem cells by promoting epigenetic remodeling and the expression of pluripotency-associated genes. Stem Cells, 28, 713–720.
24.
MannoC.S., PierceG.F., ArrudaV.R., et al. (2006). Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med., 12, 342–347.
25.
McCartyD.M., YoungS.M.Jr., and SamulskiR.J. (2004). Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu. Rev. Genet., 38, 819–845.
26.
MeilingerD., FellingerK., BultmannS., et al. (2009). Np95 interacts with de novo DNA methyltransferases, Dnmt3a and Dnmt3b, and mediates epigenetic silencing of the viral CMV promoter in embryonic stem cells. EMBO Rep., 10, 1259–1264.
27.
NakagawaM., KoyanagiM., TanabeK., et al. (2008). Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat. Biotechnol., 26, 101–106.
28.
NakaiH., IwakiY., KayM.A., and CoutoL.B. (1999). Isolation of recombinant adeno-associated virus vector–cellular DNA junctions from mouse liver. J. Virol., 73, 5438–5447.
29.
NakaiH., YantS.R., StormT.A., et al. (2001). Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J. Virol., 75, 6969–6976.
30.
NathwaniA.C., TuddenhamE.G., RangarajanS., et al. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med., 365, 2357–2365.
31.
OkadaM., and YonedaY. (2011). The timing of retroviral silencing correlates with the quality of induced pluripotent stem cell lines. Biochim. Biophys. Acta, 1810, 226–235.
32.
OkitaK., IchisakaT., and YamanakaS. (2007). Generation of germline-competent induced pluripotent stem cells. Nature, 448, 313–317.
33.
OkitaK., NakagawaM., HyenjongH., et al. (2008). Generation of mouse induced pluripotent stem cells without viral vectors. Science, 322, 949–953.
34.
SchneppB.C., ClarkK.R., KlemanskiD.L., et al. (2003). Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J. Virol., 77, 3495–3504.
35.
SimonelliF., MaguireA.M., TestaF., et al. (2010). Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol. Ther., 18, 643–650.
36.
SommerC.A., StadtfeldM., MurphyG.J., et al. (2009). Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. Stem Cells, 27, 543–549.
37.
SongS., MorganM., EllisT., et al. (1998). Sustained secretion of human α-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc. Natl. Acad. Sci. U.S.A., 95, 14384–14388.
38.
SongS., EmburyJ., LaipisP.J., et al. (2001a). Stable therapeutic serum levels of human α-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors. Gene Ther., 8, 1299–1306
39.
SongS., LaipisP.J., BernsK.I., and FlotteT.R. (2001b). Effect of DNA-dependent protein kinase on the molecular fate of the rAAV2 genome in skeletal muscle. Proc. Natl. Acad. Sci. U.S.A., 98, 4084–4088
40.
SongS., LuY., ChoiY.K., et al. (2004). DNA-dependent PK inhibits adeno-associated virus DNA integration. Proc. Natl. Acad. Sci. U.S.A., 101, 2112–2116.
41.
StadtfeldM., and HochedlingerK. (2010). Induced pluripotency: History, mechanisms, and applications. Genes Dev., 24, 2239–2263.
42.
SunN., PanettaN.J., GuptaD.M., et al. (2009). Feeder-free derivation of induced pluripotent stem cells from adult human adipose stem cells. Proc. Natl. Acad. Sci. U.S.A., 106, 15720–15725.
43.
TakahashiK., and YamanakaS. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126, 663–676.
44.
TakahashiK., TanabeK., OhnukiM., et al. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131, 861–872.
45.
TakenakaC., NishishitaN., TakadaN., et al. (2010). Effective generation of iPS cells from CD34+ cord blood cells by inhibition of p53. Exp. Hematol., 38, 154–162.
46.
WarrenL., ManosP.D., AhfeldtT., et al. (2010). Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell, 7, 618–630.
47.
WeltnerJ., AnisimovA., AlitaloK., et al. (2012a). Induced pluripotent stem cell clones reprogrammed via recombinant adeno-associated virus-mediated transduction contain integrated vector sequences. J. Virol., 86, 4463–4467
48.
WeltnerJ., AnisimovA., AlitaloK., et al. (2012b). iPSC clones reprogrammed via rAAV-mediated transduction contain integrated vector sequences. J. Virol., 86, 4463–4467
49.
XiaX., ZhangY., ZiethC.R., and ZhangS.C. (2007). Transgenes delivered by lentiviral vector are suppressed in human embryonic stem cells in a promoter-dependent manner. Stem Cells Dev., 16, 167–176.
50.
YangC.S., LopezC.G., and RanaT.M. (2011). Discovery of NSAID and anticancer drugs enhancing reprogramming and IPS cell generation. Stem Cells, 29, 1528–1536.
51.
YoshidaY., TakahashiK., OkitaK., et al. (2009). Hypoxia enhances the generation of induced pluripotent stem cells. Cell Stem Cell, 5, 237–241.
52.
ZhangC., CortezN.G., and BernsK.I. (2007). Characterization of a bipartite recombinant adeno-associated viral vector for site-specific integration. Hum. Gene Ther., 18, 787–797.
53.
ZhouH., WuS., JooJ.Y., et al. (2009). Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell, 4, 381–384.
54.
ZhouW., and FreedC.R. (2009). Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells. Stem Cells, 27, 2667–2674.
55.
ZhuY., LiuT., SongK., et al. (2008). Adipose-derived stem cell: A better stem cell than BMSC. Cell Biochem. Funct., 26, 664–675.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
